Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Mise à jour : Il y a 4 ans
Référence : NCT00411528

Extrait

The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer. Additionally, this study will assess the response on measureable disease and the effects on patient-reported outcomes.


Critère d'inclusion

  • Metastatic Hormone-Refractory Prostate Cancer


Liens